fashion -WSS

fashion

author：comprehensive 2025-09-28 00:53:42 - browse：5

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Takeda, Janssen join wearable maker to measure scratching

focus

WSS

Mayo Clinic plans $5B tech

PBMs drew scrutiny in House hearing — and so did pharma

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

ReNAgade cuts staff seven months after raising $300 million

Fed up with FDA, ALS advocates consider a take

Covid’s new normal has set in amid another rise in cases

focus

fashion

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Why the drug industry's warnings on the IRA's impact fall short

Moonlake's readout produced a cash windfall. Risks remain

Disappointing trial forces Pfizer to pivot on obesity medicine plans

How to save PrEP access — and even expand it

ReNAgade cuts staff seven months after raising $300 million

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Chamber of Commerce, DOJ clash in court over drug prices

Activists slam private health insurers over coverage restrictions

Why the drug industry's warnings on the IRA's impact fall short

hotspot

What don’t we know about an Alzheimer’s drug side effect?

With clinical trial data readouts, here's how to spot spin

Disappointing trial forces Pfizer to pivot on obesity medicine plans

BIO selects John Crowley as new CEO

BIO selects John Crowley as new CEO

Midwives could help bridge maternal health disparities in the U.S.

Wikipedia

focus

knowledge

leisure time